FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Britain Courts Anthropic Amid US Defense Department Dispute 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
OXFORD, UNITED KINGDOM, Aug. 03, 2017 -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and Clostridium difficile infection, announces that Mr Erik Ostrowski, CFO of Summit, will present a corporate overview at the Canaccord Genuity Growth Conference on 9 August 2017 at 10:30am EDT in Boston, Massachusetts, US.
A live audio webcast of the presentation will be available through the Investors section on the Company’s website, www.summitplc.com. A replay of the webcast will be available soon after the live presentation.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
-END-
For more information, please contact: Summit Therapeutics Glyn Edwards / Richard Pye (UK office) Tel: +44 (0)1235 443 951 Erik Ostrowski / Michelle Avery (US office) +1 617 225 4455 Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Tony Rawlinson Tel: +44 (0)20 7213 0880 N+1 Singer (Broker) Aubrey Powell / Lauren Kettle Tel: +44 (0)20 7496 3000 MacDougall Biomedical Communications (US media contact) Tel: +1 781 235 3060 Karen Sharma [email protected] Consilium Strategic Communications (Financial public relations, UK) Tel: +44 (0)20 3709 5700 Mary-Jane Elliott / Sue Stuart / [email protected] Jessica Hodgson / Lindsey Neville
